Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could end painful liver biopsies for millions

NCT ID NCT04616664

Diagnosis Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new blood test called LLIFT to see if it can accurately diagnose fatty liver disease and its severe form, NASH, without needing a liver biopsy. Researchers enrolled 158 people at high risk for metabolic syndrome. The LLIFT test combines patient information like age, weight, and diabetes status with blood markers and genetic data. If proven accurate, this test could make screening for liver disease much easier and safer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LLIFT (Lille LIver Fat Test) – a blood test combining clinical data, lab values, and genetic markers
What this could lead to
If successful, this could provide a simple, non-invasive blood test to diagnose fatty liver disease and NASH, replacing the need for a liver biopsy in many patients.
What could go wrong
This is a diagnostic accuracy study, not a treatment trial. The test may not be accurate enough to replace biopsy in all cases, and results may not apply to lower-risk populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

158 people

The number who actually took part.

Started

Feb 2021

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients are followed in the cardiology, endocrinology, hepatology, hepatologic surgery and bariatric surgery units of the CHU de Lille and regional centers and presente type 2 diabetes or blood pressure hypertension associated with increased hepatic enzyme. Patients will be referred to the hepatology units and included in the study

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with 1 at least of the following metabolic criteria : * BMI \> 30 kg/m², * Type 2 diabetes (glycemia \> 1.26 g/L or under therapy) * hypertension (\> 140 mmHg / 90 mmHg or under therapy) associated with increased hepatic enzymes * Indication of NAFLD evaluation * Patients written consent * Affiliated to a social insurance Exclusion Criteria: * Contraindications for liver biopsy or MRI. * Other confounding cause of liver disease (HCV, HBV, HCC, autoimmune liver disease, Hemochromatosis, Wilson disease. * alcohol consumption higher than 140g/week for women and 210g/week for men * Previous history of alcohol abuse (addiction). * Eluding stent \< 6 month or acute coronary syndrome within 1 year or non-eluding stent within 6 weeks. * Hepatocellular carcinoma * Being processed Cancer (chemotherapy, radiotherapy or hormone therapy) * Pregnant or breastfeeding women. * Drug abuse within the past year. * Mentally unbalanced patients, under supervision or guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASH - nonalcoholic steatohepatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease metabolic syndrome X Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASH - nonalcoholic steatohepatitis Obesity

Contacts and locations

Locations

  • CH ARRAS

    Arras, France

  • CH LENS

    Lens, France

  • CH de Douai

    Douai, France

  • Ch Valenciennes

    Valenciennes, France

  • Chu Amiens Picardie

    Amiens, France

  • GHIRCL saint Philibert

    Lomme, France

  • Hop Claude Huriez Chu Lille

    Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.